PBA affects nearly 2 million people with a variety of underlying neurologic conditionsREF
PBA Symptom Prevalence Estimates From PRISM Registry (n=5290)*REF
*The Center for Neurologic Study-Lability Scale (CNS-LS). The CNS-LS has been validated in patients with MS and ALS. A score ≥13 may suggest PBA symptoms and merits further diagnostic assessment. The PBA estimates in the Avanir-sponsored studies and surveys tend to differ from what has been previously reported in literature. Sampling bias may have occurred given the limited response to the surveys.
PRISM brings greater clarity to the estimated prevalence of PBA symptoms
PRISM reveals 36.7% of patients screened had symptoms suggestive of PBAREF
The largest ever observational study of PBA symptom prevalence was conducted with 5,290 patients enrolled at 173 sites across the USA
Assessed the prevalence of PBA symptoms across 6 underlying neurologic conditions in a clinical practice setting
Assessed PBA symptoms as measured by CNS-LS scores*
Quality of Life impact of neurologic condition and psychotropic medication use were also measured
*The Center for Neurologic Study-Lability Scale (CNS-LS). The CNS-LS has been validated in patients with MS and ALS. A score ≥13 may suggest PBA symptoms and merits further diagnostic assessment.
Projected Prevalence of PBA symptoms in a typical 120-bed nursing facilityREF
|Neurologic Diagnosis||Number of Residents with Neurologic Diagnosis*||Projected Number of Residents with PBA Symptoms†|
†Projection is made utilizing prevalence numbers from PRISM study based on CNS-LS ≥13.
PRISM study design and limitations
Non-interventional PBA registry of at-risk underlying neurologic populations
Assessed PBA symptoms as measured by CNS-LS scores